1034 Lipoxin A4 diminishes mast cell activation and allergic contact hypersensitivity
Atopic dermatitis (AD) is characterized by type 2 cytokines in lesional skin. In AD, IgE-activated dermal mast cells may perpetuate type 2 dysregulation through the release of inflammatory granules and de novo transcribed cytokines. Current MC-therapies primarily target granule release and have limited success in AD treatment, necessitating exploration for improved MC-targeting agents. Immunoresolvins, such as lipoxin A4 (LXA4) are therapeutic in murine asthma models, and may be efficacious for treating allergic inflammation in the skin.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: H. Baxendell, A. Haduch, J. Alwine, N. Naumov, L.D. Falo, T. Sumpter Tags: Innate Immunity, Microbiology, Inflammation Source Type: research